Is Allergan plc (NYSE:AGN) A Great Dividend Stock?

Dividends can be underrated but they form a large part of investment returns, playing an important role in compounding returns in the long run. In the last few years Allergan plc (NYSE:AGN) has paid a dividend to shareholders. Today it yields 1.9%. Does Allergan tick all the boxes of a great dividend stock? Below, I’ll take you through my analysis.

View our latest analysis for Allergan

5 questions to ask before buying a dividend stock

When assessing a stock as a potential addition to my dividend Portfolio, I look at these five areas:

  • Does it pay an annual yield higher than 75% of dividend payers?
  • Does it consistently pay out dividends without missing a payment of significantly cutting payout?
  • Has dividend per share amount increased over the past?
  • Is is able to pay the current rate of dividends from its earnings?
  • Will it have the ability to keep paying its dividends going forward?
NYSE:AGN Historical Dividend Yield December 7th 18
NYSE:AGN Historical Dividend Yield December 7th 18

Does Allergan pass our checks?

Allergan has a trailing twelve-month payout ratio of 37%, meaning the dividend is sufficiently covered by earnings. However, going forward, analysts expect AGN’s payout to fall to 18% of its earnings, which leads to a dividend yield of around 2.0%. In addition to this, EPS is also forecasted to fall to $-2.01 in the upcoming year. The lower EPS on top of a lower payout ratio will lead to a fall in dividend payment moving forward.

When thinking about whether a dividend is sustainable, another factor to consider is the cash flow. Cash flow is important because companies with strong cash flow can usually sustain higher payout ratios.

If there’s one type of stock you want to be reliable, it’s dividend stocks and their stable income-generating ability. Unfortunately, it is really too early to view Allergan as a dividend investment. It has only been consistently paying dividends for 2 years, however, standard practice for reliable payers is to look for a 10-year minimum track record.

Relative to peers, Allergan produces a yield of 1.9%, which is on the low-side for Pharmaceuticals stocks.

Next Steps:

If you are building an income portfolio, then Allergan is a complicated choice since it has some positive aspects as well as negative ones. But if you are not exclusively a dividend investor, the stock could still be an interesting investment opportunity. Given that this is purely a dividend analysis, I urge potential investors to try and get a good understanding of the underlying business and its fundamentals before deciding on an investment. Below, I’ve compiled three key aspects you should further research:

  1. Future Outlook: What are well-informed industry analysts predicting for AGN’s future growth? Take a look at our free research report of analyst consensus for AGN’s outlook.
  2. Valuation: What is AGN worth today? Even if the stock is a cash cow, it’s not worth an infinite price. The intrinsic value infographic in our free research report helps visualize whether AGN is currently mispriced by the market.
  3. Dividend Rockstars: Are there better dividend payers with stronger fundamentals out there? Check out our free list of these great stocks here.

To help readers see past the short term volatility of the financial market, we aim to bring you a long-term focused research analysis purely driven by fundamental data. Note that our analysis does not factor in the latest price-sensitive company announcements.

The author is an independent contributor and at the time of publication had no position in the stocks mentioned. For errors that warrant correction please contact the editor at editorial-team@simplywallst.com.